Results 241 to 250 of about 223,933 (345)

Clues of HLAs, metabolic SNPs, and epigenetic factors in T cell-mediated drug hypersensitivity reactions. [PDF]

open access: yesHeliyon
Molatefi R   +10 more
europepmc   +1 more source

Omeprazole Induced Rapid Drug Reaction with Eosinophilia, Systemic Symptoms, and Cross-Reactivity in Delayed-Type Hypersensitivity Associated with Proton-Pump Inhibitors: A Case Report and Literature Review [PDF]

open access: gold
Kanokkarn Pinyopornpanish   +6 more
openalex   +1 more source

Radiation Risk in 2D Mammography Screening: A Scoping Review of Modelling Strategies and Emerging AI Applications

open access: yesJournal of Medical Radiation Sciences, EarlyView.
This scoping review examined models estimating long‐term radiation risks from repeated mammography screening. While modelling indicates the risks are low, approaches vary by protocol and vendor. Emerging AI tools show promise for improving personalised risk estimation, though further development is needed for cross‐platform compatibility.
Nazli A. Moda   +3 more
wiley   +1 more source

Evaluation of the frequency and characteristics of drug hypersensitivity reactions in hospitalized children: Real life-cohort study. [PDF]

open access: yesWorld Allergy Organ J
Büyük Yaytokgil Ş   +8 more
europepmc   +1 more source

Mineral‐targeted alkaline phosphatase improves bone graft‐mediated alveolar bone defect healing in mice

open access: yesJournal of Periodontology, EarlyView.
Abstract Background Alveolar bone loss challenges tooth retention and implant placement. Freeze‐dried bone allograft (FDBA) is widely used for alveolar ridge preservation but has limitations in resorption rate and healing time. In this proof‐of‐concept study, we tested whether pro‐mineralization enzyme, tissue‐nonspecific alkaline phosphatase (TNAP ...
Kedith Sawangsri   +4 more
wiley   +1 more source

Severe allergic reaction to ustekinumab reinitiation in a pediatric patient with Crohn's disease: A case report

open access: yesJPGN Reports, EarlyView.
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy